All variations
Indications/Uses
As monotherapy and adjunct to treatment with other antiepileptics for partial seizure and primary and secondary generalized tonic-clonic seizures. Prophylaxis of bipolar disorders.
Dosage/Direction for Use
Adults: Initial Dose: Monotherapy: 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 weeks; thereafter the dose is increased by maximum of 50-100 mg every 1-2 weeks. Maintenance Dose: 100-200 mg daily.
Bipolar Disorder: 100-200 mg daily.
Bipolar Disorder: 100-200 mg daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to lamotrigine or to any of the excipients of Motrigine/Motrigine 100.
Special Precautions
Lamotrigine should be given with caution to patients with hepatic or renal impairment. Patients receiving lamotrigine should be closely monitored especially for changes in hepatic, renal and clotting functions.
Use in pregnancy: The use of Lamotrigine is not recommended for use in pregnancy.
Use in lactation: Lamotrigine is distributed into breast milk and therefore, should be avoided during breastfeeding.
Use in pregnancy: The use of Lamotrigine is not recommended for use in pregnancy.
Use in lactation: Lamotrigine is distributed into breast milk and therefore, should be avoided during breastfeeding.
Use In Pregnancy & Lactation
Use in pregnancy: The use of Lamotrigine is not recommended for use in pregnancy.
Use in lactation: Lamotrigine is distributed into breast milk and therefore, should be avoided during breastfeeding.
Use in lactation: Lamotrigine is distributed into breast milk and therefore, should be avoided during breastfeeding.
Adverse Reactions
Skin rashes may occur during therapy with lamotrigine. Severe skin reactions including Stevens-Johnson syndrome were reported especially in children and usually occur within 8 weeks of starting lamotrigine.
Symptoms eg, fever, malaise, flu-like symptoms, drowsiness, lymphadenopathy, facial edema, and rarely, hepatic dysfunction, leukopenia and thrombocytopenia have also been reported with rashes as part of hypersensitivity syndrome.
Other adverse effects include angioedema and photosensitivity, diplopia, blurred vision and conjunctivitis and dizziness, drowsiness, insomnia, headache, ataxia, nystagmus, tremor, tiredness, nausea and vomiting, irritability and aggression, hallucinations, agitation and confusion. Very rarely, lupus-like reactions have been reported.
Symptoms eg, fever, malaise, flu-like symptoms, drowsiness, lymphadenopathy, facial edema, and rarely, hepatic dysfunction, leukopenia and thrombocytopenia have also been reported with rashes as part of hypersensitivity syndrome.
Other adverse effects include angioedema and photosensitivity, diplopia, blurred vision and conjunctivitis and dizziness, drowsiness, insomnia, headache, ataxia, nystagmus, tremor, tiredness, nausea and vomiting, irritability and aggression, hallucinations, agitation and confusion. Very rarely, lupus-like reactions have been reported.
Drug Interactions
There are complex interactions between antiepileptic and toxicity may be enhanced by the enzyme inducers carbamazepine, phenytoin, phenobarbital and primidone, and inhibited by valproate.
Storage
Store at temperatures not exceeding 30°C.
Shelf-Life: 36 months.
Shelf-Life: 36 months.
Action
Pharmacology: Pharmacokinetics: Lamotrigine is well-absorbed from the gastrointestinal tract and peak plasma concentrations (Cmax) occur approximately 2.5 hrs after oral dose. It is widely distributed in the body and is reported to be about 55% bound to plasma proteins. It is extensively metabolized in the liver and excreted almost entirely conjugate. It slightly induces its own metabolism and the t½ at conjugate. It slightly induces its own metabolism and the t½ in urine, principally as a glucuronide conjugate. It slightly induces its own metabolism and the t½ at steady state is reported to be about 24 hrs. Lamotrigine is distributed in breast milk.
MedsGo Class
Anticonvulsants
Features
Dosage
50 mg
Ingredients
- Lamotrigine
Packaging
Tablet 1's
Generic Name
Lamotrigine
Registration Number
DRP-3340
Classification
Prescription Drug (RX)
Product Questions
Questions
